8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 14, 2018)

Filed February 14, 2018For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb (BMY) has entered into a significant global strategic collaboration with Nektar Therapeutics to co-develop and commercialize Nektar's lead immuno-oncology program, NKTR-214. This deal involves a substantial upfront cash payment of $1.0 billion and an equity investment of $850 million by BMY. The agreement highlights BMY's continued investment in innovative oncology treatments, aiming to bolster its pipeline with promising new therapies. The collaboration provides BMY with access to NKTR-214, a novel biologic designed to stimulate the body's own immune system to fight cancer. In addition to the initial payments, Nektar is eligible for up to $1.78 billion in future milestone payments, contingent on the successful development, regulatory approval, and commercialization of the drug. This strategic move signifies BMY's commitment to expanding its oncology portfolio and pursuing potentially transformative treatments for cancer patients.

Key Highlights

  • 1BMY and Nektar Therapeutics have formed a global strategic development and commercialization collaboration for Nektar's NKTR-214 immuno-oncology program.
  • 2BMY made an upfront cash payment of $1.0 billion and an equity investment of $850 million as part of the deal.
  • 3Nektar Therapeutics is eligible to receive up to an additional $1.78 billion in milestone payments.
  • 4The milestone payments include $1.43 billion for development and regulatory achievements.
  • 5NKTR-214 is Nektar's lead immuno-oncology program, aimed at stimulating the immune system to fight cancer.
  • 6This collaboration represents a significant investment by BMY in its oncology pipeline.
  • 7The deal was announced via a joint press release filed as an exhibit to the 8-K.

Frequently Asked Questions

NKTR-214 is Nektar Therapeutics' lead immuno-oncology program. It is a biologic designed to activate the body's immune system to attack cancer cells. BMY is investing in this program as part of its strategy to strengthen its oncology pipeline with potentially innovative and effective cancer treatments.

Bristol-Myers Squibb (BMY) has committed an upfront cash payment of $1.0 billion and made an equity investment of $850 million. Additionally, Nektar Therapeutics is eligible to receive up to $1.78 billion in future milestone payments, dependent on the program's success.

This collaboration signifies BMY's proactive approach to expanding its oncology portfolio with novel therapies. By partnering on NKTR-214, BMY aims to bring a potentially groundbreaking immuno-oncology treatment to patients and reinforce its position in the competitive cancer drug market.

The upfront payments of $1.0 billion in cash and $850 million in equity represent a firm commitment from BMY. However, the substantial remaining $1.78 billion in potential milestone payments are contingent on the successful development, regulatory approvals, and commercial performance of NKTR-214, which carries inherent risks typical of drug development.